Developer docs
API playgroundTry for free, no card

Search company profiles

Black Opal Ventures

Full company profile

uuid00002rm

Namestring
Black Opal Ventures
Legal namestring
Black Opal Ventures
Websiteurl
https://www.blackopalventures.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Black Opal Ventures is a women-led venture capital firm founded in 2021 by Dr. Tara Bishop and Eileen Tanghal, both MIT alumnae, headquartered in New York. The firm invests at the intersection of healthcare, life sciences, infrastructure, and security, with a stated focus on companies using frontier technologies such as AI, bioengineering, and compute to address structural challenges. Its portfolio spans 30+ companies across healthtech (Chamber Cardio, Isaac Health, Optellum, Empatica, River Health), tech bio, infrastructure/security (AuthMind), and AI infrastructure (Parasail), with disclosed portfolio bets ranging from seed to Series A.

The firm closed its inaugural $58 million healthtech-focused fund in 2023, and its revenue model follows standard venture capital mechanics: recurring management fees (typically ~2% of committed capital during the investment period) charged to Limited Partners, plus carried interest (typically ~20%) on profits from future portfolio exits. Limited Partners comprise institutional investors, family offices, foundations, and high-net-worth individuals. The firm's go-to-market combines deal-flow channels (MIT alumni network, a Fellows program for sourcing, direct deal submissions, pitch competitions including the MIT Female Founders Pitch Competition) with proprietary community events such as the annual Brilliant Tomorrows Forum and the inaugural Global Growth Event held in London in June 2025.

The firm's competitive position rests on the complementary expertise of its co-founders: Dr. Bishop brings a physician background and value-based-care leadership from Bind (acquired by UnitedHealth Group), McKinsey, and Weill Cornell, while Tanghal brings 20+ years of venture investing at Amadeus Capital Partners, Applied Ventures, and In-Q-Tel, plus operating experience at Arm and a semiconductor startup. The firm operates with a 1–10 person team and has been recognized via the ImpactAssets 50 in both 2025 and 2026, Women of Influence in Private Markets 2022, and selection to The Bridge Conference, supporting its positioning as a differentiated impact- and women-led fund at a time when women-led VC firms remain under 6% of the US total.

Short descriptiontext

Black Opal Ventures is a New York-based, women-led venture capital firm founded in 2021 by Dr. Tara Bishop and Eileen Tanghal that invests at the intersection of healthcare, life sciences, infrastructure, and security via a $58M inaugural fund backing 30+ early-stage technology companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, healthcare technology funds, early-stage investments, infrastructure security funding, life sciences venture
Industry1 code
1Sector-Focused Venture Capital (Vertical Specialists)
CodeFSANAAADPrimaryYes
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • All Other Financial Investment Activities52399
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees
TypeSubscription Recurring
Description

Venture capital funds typically charge 2% management fees on committed capital annually during the investment period

blackopalventures.com
2Carried Interest
TypeTransaction Fee
Description

VC firms earn carried interest (typically 20%) on profits from successful portfolio company exits after returning capital to LPs

blackopalventures.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Black Opal Ventures is a women-led venture capital firm that manages an inaugural $58M healthtech-focused fund investing early-stage equity in companies at the intersection of healthcare, life sciences, infrastructure, and cybersecurity. The firm backs founders building technology-driven solutions to structural challenges, deploying capital from Limited Partners and providing strategic guidance to portfolio companies. It also operates a Fellows program to source deals and hosts proprietary events such as the Brilliant Tomorrows Forum.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Black Opal Ventures is a venture capital firm founded in 2021 by Tara Bishop and Eileen Tanghal, both MIT alumnae. The firm operates as a single investment fund focused on backing companies using technology to solve the world's biggest problems. Their investment thesis centers on the intersection of healthcare and technology, with portfolio companies spanning Healthtech, Tech Bio, Infrastructure, and Cybersecurity sectors. The firm also operates a Fellows program to source investment opportunities and conducts market research, while publishing insights and thought leadership content.

Product and service2 records
1Black Opal Ventures Fund I
CategoryVenture Capital Fund
Description

Early-stage equity investment fund focused on companies at the intersection of healthcare, life sciences, infrastructure, and cybersecurity that use technology to solve structural challenges. Provides capital, strategic guidance, and access to co-founders' clinical, technical, and policy networks.

2Black Opal Fellows Program
CategoryDeal Sourcing Program
Description

A program that engages Fellows to source investment opportunities and conduct diligence for the Black Opal Ventures fund, supporting deal flow at the intersection of healthcare, life sciences, infrastructure, and security.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment34 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Black Opal Ventures

Venture Capitalblackopalventures.com

Black Opal Ventures is a New York-based, women-led venture capital firm founded in 2021 by Dr. Tara Bishop and Eileen Tanghal that invests at the intersection of healthcare, life sciences, infrastructure, and security via a $58M inaugural fund backing 30+ early-stage technology companies.

What Black Opal Ventures does

Black Opal Ventures is a women-led venture capital firm founded in 2021 by Dr. Tara Bishop and Eileen Tanghal, both MIT alumnae, headquartered in New York. The firm invests at the intersection of healthcare, life sciences, infrastructure, and security, with a stated focus on companies using frontier technologies such as AI, bioengineering, and compute to address structural challenges. Its portfolio spans 30+ companies across healthtech (Chamber Cardio, Isaac Health, Optellum, Empatica, River Health), tech bio, infrastructure/security (AuthMind), and AI infrastructure (Parasail), with disclosed portfolio bets ranging from seed to Series A.

The firm closed its inaugural $58 million healthtech-focused fund in 2023, and its revenue model follows standard venture capital mechanics: recurring management fees (typically ~2% of committed capital during the investment period) charged to Limited Partners, plus carried interest (typically ~20%) on profits from future portfolio exits. Limited Partners comprise institutional investors, family offices, foundations, and high-net-worth individuals. The firm's go-to-market combines deal-flow channels (MIT alumni network, a Fellows program for sourcing, direct deal submissions, pitch competitions including the MIT Female Founders Pitch Competition) with proprietary community events such as the annual Brilliant Tomorrows Forum and the inaugural Global Growth Event held in London in June 2025.

The firm's competitive position rests on the complementary expertise of its co-founders: Dr. Bishop brings a physician background and value-based-care leadership from Bind (acquired by UnitedHealth Group), McKinsey, and Weill Cornell, while Tanghal brings 20+ years of venture investing at Amadeus Capital Partners, Applied Ventures, and In-Q-Tel, plus operating experience at Arm and a semiconductor startup. The firm operates with a 1–10 person team and has been recognized via the ImpactAssets 50 in both 2025 and 2026, Women of Influence in Private Markets 2022, and selection to The Bridge Conference, supporting its positioning as a differentiated impact- and women-led fund at a time when women-led VC firms remain under 6% of the US total.

Black Opal Ventures firmographics

Firmographics
Name
Black Opal Ventures
Legal name
Black Opal Ventures
Website
https://www.blackopalventures.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Black Opal Ventures is a New York-based, women-led venture capital firm founded in 2021 by Dr. Tara Bishop and Eileen Tanghal that invests at the intersection of healthcare, life sciences, infrastructure, and security via a $58M inaugural fund backing 30+ early-stage technology companies.
Ownership category
akta.pro rank

Black Opal Ventures industry classification

Industry
Product category
Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399)
SIC
Investment Advice (6282)
akta.pro primary industry
Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

  • Venture capital investing
  • Healthcare technology funds
  • Early-stage investments
  • Infrastructure security funding
  • Life sciences venture

Where Black Opal Ventures is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Black Opal Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Revenue model

  1. Management Fees: Venture capital funds typically charge 2% management fees on committed capital annually during the investment period
  2. Carried Interest: VC firms earn carried interest (typically 20%) on profits from successful portfolio company exits after returning capital to LPs

Go-to-market motion2 records

Distribution channels1 record

Marketing channels8 records

Black Opal Ventures product offering

Product offering

Core offering

Black Opal Ventures is a women-led venture capital firm that manages an inaugural $58M healthtech-focused fund investing early-stage equity in companies at the intersection of healthcare, life sciences, infrastructure, and cybersecurity. The firm backs founders building technology-driven solutions to structural challenges, deploying capital from Limited Partners and providing strategic guidance to portfolio companies. It also operates a Fellows program to source deals and hosts proprietary events such as the Brilliant Tomorrows Forum.

Product overview

Black Opal Ventures is a venture capital firm founded in 2021 by Tara Bishop and Eileen Tanghal, both MIT alumnae. The firm operates as a single investment fund focused on backing companies using technology to solve the world's biggest problems. Their investment thesis centers on the intersection of healthcare and technology, with portfolio companies spanning Healthtech, Tech Bio, Infrastructure, and Cybersecurity sectors. The firm also operates a Fellows program to source investment opportunities and conducts market research, while publishing insights and thought leadership content.

Differentiator

Problem solved

Functional benefit

Products and services

  • Black Opal Ventures Fund I Early-stage equity investment fund focused on companies at the intersection of healthcare, life sciences, infrastructure, and cybersecurity that use technology to solve structural challenges. Provides capital, strategic guidance, and access to co-founders' clinical, technical, and policy networks.
  • Black Opal Fellows Program A program that engages Fellows to source investment opportunities and conduct diligence for the Black Opal Ventures fund, supporting deal flow at the intersection of healthcare, life sciences, infrastructure, and security.

Companies that use Black Opal Ventures

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Black Opal Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Black Opal Ventures partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Black Opal Ventures competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Black Opal Ventures social profiles

Digital presence

Black Opal Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Black Opal Ventures leadership team

Management profile

Number of profiles

Profiles2 records

Black Opal Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Black Opal Ventures M&A and investment

M&A and investment

M&A

Investments34 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Black Opal Ventures

What does Black Opal Ventures do?

Black Opal Ventures is a women-led venture capital firm that manages an inaugural $58M healthtech-focused fund investing early-stage equity in companies at the intersection of healthcare, life sciences, infrastructure, and cybersecurity. The firm backs founders building technology-driven solutions to structural challenges, deploying capital from Limited Partners and providing strategic guidance to portfolio companies. It also operates a Fellows program to source deals and hosts proprietary events such as the Brilliant Tomorrows Forum.

Is Black Opal Ventures a public or private company?

Black Opal Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Black Opal Ventures founded?

Black Opal Ventures was founded in 2021. It employs 1 to 10 people.

Where is Black Opal Ventures based?

Black Opal Ventures is headquartered in New York, United States, in the North America region.

How does Black Opal Ventures make money?

Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.

Does Black Opal Ventures have an API?

No public API is recorded for Black Opal Ventures.

What industry is Black Opal Ventures in?

Black Opal Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineTiny Health Raises $33M Series B to Establish Microbiome Intelligence as the Standard of CareTiny Health raised a $33 million Series B led by B Capital, bringing total funding to $46 million. The company will use the capital to advance clinical research, expand practitioner education, and scale its B2B platform. It also launched a $5 million Microbiome Research Program to support microbiome science.FinSMEsTiny Health Raises $33M in Series B FundingTiny Health raised $33M in Series B funding led by B Capital, bringing total funding to $46M. The Austin-based microbiome platform will use the funds for clinical research, practitioner education, and scaling its B2B platform and AI. It also committed $5M to a microbiome research program.Tech.euSCI Semiconductor raises £5M to ramp up production of memory-safe chipsSCI Semiconductor raised £5 million to accelerate production of its ICENI memory-safe chips. The Sheffield-based company has secured over £2 million in orders and government contracts totaling £7.7 million. It plans to create 15 new jobs and develop a new generation of chips.MorningstarCottage Health and Thesis Announce Innovation Partnership to Expand Clinical Capacity and Support World-Class Patient CareCottage Health and Thesis announced a partnership to deploy AI care team agents across clinical workflows, marking Thesis's first health system collaboration. Cottage Health, a California health system, will use the platform to strengthen patient engagement and follow-up. Thesis recently raised $45 million in Series A funding.The Pharma LetterAnsa secures $54.4 million to expand enzymatic DNA synthesis platformUS biotech Ansa Biotechnologies has raised $45.2 million in a Series B financing round with an additional $9.2 million in committed capital, bringing the total to $54.4 million, to expand its enzymatic DNA synthesis platform. The round was led by Cerberus Ventures with participation from Fall Line Capital, AIM13, Black Opal Ventures, and existing investors Blue Water Life Science Advisors and Altitude Life Science Ventures.FiercePharmaAnsa snares $54.4M in series B financing to boost its DNA synthesis platformAnsa Biotechnologies, a San Francisco-based biotech founded in 2018, raised $54.4 million in an oversubscribed series B financing round to expand its DNA synthesis production capacity in the U.S. The round was led by Cerberus Ventures with participation from Blue Water Life Science Advisors, Altitude Life Science Ventures, and new investors Fall Line Capital, AIM13, and Black Opal Ventures. The company, which has now raised over $134 million total, uses an enzyme-based platform to synthesize DNA for biopharmaceutical researchers creating diagnostics, therapeutics, and biomanufactured materials.FirstWordAnsa collects $54.4M series B to scale DNA synthesisAnsa Biotechnologies raised $54.4 million in an oversubscribed series B round, consisting of $45.2 million in actual funding plus $9.2 million in committed capital, with Cerberus Ventures leading alongside Fall Line Capital, AIM13, Black Opal Ventures, and existing backers Blue Water Life Science Advisors and Altitude Life Science Ventures. The company plans to use the proceeds to scale its enzymatic DNA synthesis platform, which can directly produce 'ansamers' exceeding 1000 bases — longer sequences than conventional methods have been able to access. The technology targets applications in gene and cell therapy, vaccines, and synthetic biology, with investors positioning it as a potential replacement for outdated synthesis processes.ForbesHow Women VCs Are Shaping The Future Of HealthcareBlack Opal Ventures, a women-led healthcare venture firm founded by Dr. Tara Bishop and Eileen Tanghal, raised $55 million from institutional investors and $8 million from individual investors. The firm targets frontier technology and healthcare innovation, with portfolio companies like Outpace Bio and Conceivable. It aims to reshape an industry where women-founded startups receive less than 2% of U.S. venture funding.Business Wire BlogBlack Opal Ventures Releases Annual Impact Report, Spotlighting Frontier Technology Companies Solving Healthcare’s Complex ChallengesBlack Opal Ventures released its 2024 Impact Report, highlighting its portfolio companies using frontier technologies like generative AI, robotics, bioengineering, and advanced computing to address healthcare challenges. The firm cites U.S. healthcare spending expected to exceed $6 trillion by 2028 and aligns with UN Sustainable Development Goals.VC News DailyEmpatica Closes Series B FundingEmpatica Inc announced the successful closing of its Series B financing round, led by Sanofi Ventures and RA Capital Management with participation from Black Opal Ventures. The funding will support expansion of the company's suite of digital biomarkers used in patient care and as digital endpoints in clinical trials. The company, a pioneer in AI-driven continuous remote health monitoring, offers its flagship wearable EmbracePlus to institutional research partners.